Skip Navigation


Human Molecular Genetics Advance Access originally published online on June 30, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
13/16/1763    most recent
ddh192v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (28)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Fusco, F.
Right arrow Articles by Ursini, M. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fusco, F.
Right arrow Articles by Ursini, M. V.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, 2004, Vol. 13, No. 16 1763-1773
DOI: 10.1093/hmg/ddh192
Human Molecular Genetics, Vol. 13, No. 16 © Oxford University Press 2004; all rights reserved

Molecular analysis of the genetic defect in a large cohort of IP patients and identification of novel NEMO mutations interfering with NF-{kappa}B activation

Francesca Fusco1,{dagger}, Tiziana Bardaro1,{dagger}, Giorgia Fimiani1, Vincenzo Mercadante1, Maria Giuseppina Miano1, Geppino Falco1, Alain Israël2, Gilles Courtois2,{ddagger}, Michele D'Urso1 and Matilde Valeria Ursini1,*

1Institute of Genetics and Biophysics, Adriano Buzzati Traverso-CNR, Naples, Italy and 2Unité de Biologie Moléculaire de l' Expression Génique, Institut Pasteur, Paris, France

Received April 8, 2004; Revised May 25, 2004; Accepted June 11, 2004

Incontinentia Pigmenti (IP) is an X-linked genodermatosis that is lethal for males and present in females with abnormal skin pigmentation and high variable clinical signs, including retinal detachment, anodontia, alopecia, nail dystrophy and nervous system defects. The NF-{kappa}B essential modulator (NEMO) gene, responsible for IP, encodes the regulatory subunit of the I{kappa}B kinase (IKK) complex required for nuclear factor {kappa}B (NF-{kappa}B) activation. We analyzed the NEMO gene in 122 IP patients and identified mutations in 83 (36 familiar and 47 sporadic cases). The recurrent NEMO exon 4–10 deletion that is the major cause of the disease was present in 73 females (59.8%). In addition 10 point alterations (8.2% of females) were identified: three frameshift, three nonsense, three missense and one in-frame deletion of a single amino acid. We measured the effects of these NEMO point-mutations on NF-{kappa}B signaling in nemo(–/–) deficient murine pre-B cells. A mutation in the N-terminal domain, required for IKK assembly, reduced but did not abolish NF-{kappa}B activation following lipopolysaccharide stimulation. Mutations that disrupt the C-terminal domain, required for the recruitment of upstream factors, showed lower or no NF-{kappa}B activation. A phenotype score based on clinical features of our IP patients was applied for summarizing disease severity. The score did not correlate with mutation type or domain affected indicating that other factors influence the severity of IP. Such a factor is likely to be X-inactivation. Indeed, 64% of our patients have extremely skewed X-inactivation pattern (≥80 : 20). Overall IP pathogenesis thus depends on a combination of X-inactivation and protein domain that recruit upstream factors and activate NF-{kappa}B.

* To whom correspondence should be addressed. Email: ursini{at}igb.cnr.it


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
M. M. Souto-Carneiro, R. Fritsch, N. Sepulveda, M. J. Lagareiro, N. Morgado, N. S. Longo, and P. E. Lipsky
The NF-{kappa}B Canonical Pathway Is Involved in the Control of the Exonucleolytic Processing of Coding Ends during V(D)J Recombination
J. Immunol., January 15, 2008; 180(2): 1040 - 1049.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
H. Sebban-Benin, A. Pescatore, F. Fusco, V. Pascuale, J. Gautheron, S. Yamaoka, A. Moncla, M. V. Ursini, and G. Courtois
Identification of TRAF6-dependent NEMO polyubiquitination sites through analysis of a new NEMO mutation causing incontinentia pigmenti
Hum. Mol. Genet., December 1, 2007; 16(23): 2805 - 2815.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
P. Falabella, P. Varricchio, B. Provost, E. Espagne, R. Ferrarese, A. Grimaldi, M. de Eguileor, G. Fimiani, M. V. Ursini, C. Malva, et al.
Characterization of the I{kappa}B-like gene family in polydnaviruses associated with wasps belonging to different Braconid subfamilies
J. Gen. Virol., January 1, 2007; 88(1): 92 - 104.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Vinolo, H. Sebban, A. Chaffotte, A. Israel, G. Courtois, M. Veron, and F. Agou
A Point Mutation in NEMO Associated with Anhidrotic Ectodermal Dysplasia with Immunodeficiency Pathology Results in Destabilization of the Oligomer and Reduces Lipopolysaccharide- and Tumor Necrosis Factor-mediated NF-{kappa}B Activation
J. Biol. Chem., March 10, 2006; 281(10): 6334 - 6348.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.